Statement re. online comment

MyHealthChecked PLC

09 May 2023

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

MyHealthChecked PLC

("MyHealthChecked" or the "Company")

Statement re. online comment

MyHealthChecked PLC (AIM: MHC), the consumer home-testing healthcare company, notes online comment regarding the MyHealthChecked portfolio of at-home wellness tests now being available via a major UK retail partner.

As reported in the recent preliminary results on 3 April 2023, MHC is actively developing B2B2C customer relationships in preparation to launch an expanded portfolio of at-home wellness tests nationwide in 2023.

The Company is aware that MyHealthChecked products have been added temporarily and in draft to a retail partner's website, however no formal agreement has been signed and the Company remains at an advanced stage of negotiations. Further updates will be made to shareholders in due course.

For further information contact:

MyHealthChecked PLC		www.myhealthchecked.com
Penny McCormick, Chief Executive Officer		via Walbrook PR
SPARK Advisory Partners Limited (NOMAD)		Tel: [phone]
Neil Baldwin
Dowgate Capital Limited (Broker)		Tel: [phone]
David Poutney / Nicholas Chambers
Walbrook PR Ltd (Media & IR)	Tel: [phone] or [e-mail]
Paul McManus / Alice Woodings		Mob: [phone]

About MyHealthChecked PLC (https://investors.myhealthchecked.com/)

MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company focused on a range of at-home healthcare and wellness tests.

MyHealthChecked is the umbrella brand of a range of at-home rapid tests, as well as DNA, RNA and blood sample collection kits which have been created to support customers on their journeys to wellness. The tests are lateral-flow self-tests, whilst the sample collection kits enable the collection of blood, urine, nasal or mouth swab samples that are analysed in partner laboratories for a range of biomarkers. The tests will also be made available online and will be viable for over-the-counter purchase. 

The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by UK-based experts.

 

END